See more : Lument Finance Trust, Inc. (LFT-PA) Income Statement Analysis – Financial Results
Complete financial analysis of EyePoint Pharmaceuticals, Inc. (EYPT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of EyePoint Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Permex Petroleum Corporation (OIL.CN) Income Statement Analysis – Financial Results
- Cedar Realty Trust, Inc. (CDR) Income Statement Analysis – Financial Results
- Pan American Energy Corp. (PNRG.CN) Income Statement Analysis – Financial Results
- Shenzhen Expressway Corporation Limited (SHZNY) Income Statement Analysis – Financial Results
- Infimer Ltd (INFR-M.TA) Income Statement Analysis – Financial Results
EyePoint Pharmaceuticals, Inc. (EYPT)
About EyePoint Pharmaceuticals, Inc.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.02M | 41.40M | 36.94M | 34.44M | 20.37M | 2.96M | 7.54M | 1.62M | 26.57M | 3.47M | 2.14M | 3.53M | 4.97M | 23.05M | 12.16M | 3.48M | 2.24M | 1.47M | 629.52K | 265.23K | 74.35K | 516.32K |
| Cost of Revenue | 4.63M | 8.33M | 8.18M | 5.82M | 2.69M | 18.50M | 0.00 | 815.00K | 14.38M | 78.00K | 9.57M | 7.01M | 7.04M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.39M | 33.08M | 28.76M | 28.61M | 17.68M | -15.54M | 7.54M | 805.00K | 12.18M | 3.40M | -7.43M | -3.48M | -2.07M | 23.05M | 12.16M | 3.48M | 2.24M | 1.47M | 629.52K | 265.23K | 74.35K | 516.32K |
| Gross Profit Ratio | 89.93% | 79.89% | 77.86% | 83.09% | 86.81% | -524.86% | 100.00% | 49.69% | 45.86% | 97.75% | -346.71% | -98.67% | -41.77% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 64.66M | 49.64M | 28.50M | 17.42M | 15.37M | 16.18M | 14.88M | 14.38M | 12.09M | 9.57M | 7.01M | 7.04M | 6.86M | 6.99M | 8.01M | 14.43M | 20.03M | 11.70M | 6.29M | 4.87M | 3.08M | 1.80M |
| General & Administrative | 40.10M | 34.82M | 25.58M | 20.73M | 17.94M | 11.55M | 11.24M | 9.01M | 8.06M | 7.47M | 7.17M | 6.87M | 8.10M | 6.97M | 8.79M | 13.95M | 13.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 11.69M | 25.51M | 27.50M | 25.29M | 29.77M | 1.51M | 1.51M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -969.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 51.79M | 60.32M | 53.08M | 46.02M | 47.71M | 13.06M | 11.24M | 9.01M | 8.06M | 7.47M | 7.17M | 6.87M | 8.10M | 6.97M | 8.79M | 13.95M | 12.98M | 15.88M | 3.81M | 1.60M | 565.51K | 0.00 |
| Other Expenses | 0.00 | 2.05M | 2.46M | 2.46M | 2.46M | 14.84M | 8.31M | 13.98M | 3.00K | 7.26M | 6.23M | 19.79M | 3.25M | 3.25M | 0.00 | 71.20M | 4.77M | 1.56M | 781.71K | 27.35K | 25.42K | 0.00 |
| Operating Expenses | 115.05M | 112.02M | 84.04M | 65.90M | 65.54M | 29.24M | 26.12M | 23.39M | 20.14M | 17.04M | 14.17M | 13.91M | 14.97M | 13.96M | 16.80M | 28.38M | 37.78M | 29.14M | 10.88M | 6.50M | 3.67M | 1.80M |
| Cost & Expenses | 121.09M | 120.34M | 92.22M | 71.73M | 68.23M | 29.24M | 26.12M | 23.39M | 20.14M | 17.04M | 14.17M | 13.91M | 14.97M | 13.96M | 16.80M | 28.38M | 37.78M | 29.14M | 10.88M | 6.50M | 3.67M | 1.80M |
| Interest Income | 6.95M | 2.13M | 292.00K | 58.00K | 1.05M | 101.00K | 91.00K | 72.00K | 19.00K | 6.00K | 16.00K | 38.00K | 30.00K | 27.00K | 162.00K | 648.00K | 300.00K | 300.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.25M | 3.19M | 5.50M | 7.26M | 6.18M | 720.00K | 720.00K | 0.00 | 0.00 | 1.00K | 2.00K | 0.00 | 1.00K | 13.00K | 0.00 | 507.00K | 1.94M | 3.37M | 3.37M | 3.92K | 3.92K | 0.00 |
| Depreciation & Amortization | 464.00K | 2.45M | 2.77M | 2.65M | 2.60M | 2.65M | 815.00K | 815.00K | 882.00K | 917.00K | 994.00K | 2.23M | 3.36M | 3.33M | 3.44M | 397.00K | 8.72M | 8.70M | 1.24M | 240.94K | 212.09K | 516.32K |
| EBITDA | -69.00M | -96.62M | -50.15M | -35.49M | -48.01M | -36.99M | -18.58M | -17.67M | -20.87M | 7.30M | -12.65M | -11.04M | -22.78M | -5.49M | 9.09M | -24.00K | -75.65M | -22.05M | -18.98M | -9.44M | -6.00M | -3.39M |
| EBITDA Ratio | -149.94% | -180.56% | -142.19% | -100.97% | -217.76% | -883.92% | -246.40% | -1,344.07% | 24.17% | -364.09% | -560.66% | 121.38% | -224.17% | 40.92% | -8.52% | 773.56% | 2,814.09% | -1,504.38% | -1,235.68% | -2,643.41% | -4,552.30% | -247.68% |
| Operating Income | -75.07M | -78.94M | -55.28M | -37.29M | -47.86M | -26.27M | -18.58M | -21.77M | 6.42M | -13.49M | -12.03M | -25.21M | -10.00M | 9.09M | -4.64M | -24.90M | -35.54M | -27.68M | -10.25M | -6.24M | -3.60M | -1.80M |
| Operating Income Ratio | -163.13% | -190.65% | -149.64% | -108.28% | -235.02% | -887.34% | -246.40% | -1,344.07% | 24.17% | -388.42% | -561.41% | -715.00% | -201.47% | 39.44% | -38.12% | -716.37% | -1,590.25% | -1,888.63% | -1,628.79% | -2,351.37% | -4,838.64% | -347.68% |
| Total Other Income/Expenses | 4.36M | -2.62M | -3.14M | -8.10M | -8.93M | -63.17M | -26.90M | 91.00K | 72.00K | 22.00K | 5.00K | 14.00K | 207.00K | 1.16M | -315.00K | 1.17M | 8.85M | -61.21M | -17.73M | 9.32M | -807.00 | -1.80M |
| Income Before Tax | -70.71M | -102.25M | -58.42M | -45.39M | -56.79M | -53.17M | -18.49M | -21.70M | 6.44M | -13.49M | -12.02M | -25.00M | -8.85M | 8.78M | -3.46M | -76.15M | -127.20M | -27.98M | -11.49M | -5.22M | -3.60M | -2.25M |
| Income Before Tax Ratio | -153.66% | -246.97% | -158.14% | -131.82% | -278.88% | -1,795.71% | -245.19% | -1,339.63% | 24.25% | -388.28% | -560.76% | -709.13% | -178.17% | 38.07% | -28.47% | -2,190.82% | -5,691.41% | -1,909.47% | -1,824.63% | -1,969.97% | -4,839.72% | -436.07% |
| Income Tax Expense | 83.00K | 22.26M | 5.50M | 7.26M | 6.18M | -25.56M | -815.00K | -155.00K | 96.00K | -130.00K | -117.00K | -169.00K | -218.00K | 23.00K | -951.00K | -483.00K | -23.53M | -7.07M | -303.15K | -2.67M | -1.74M | -1.80M |
| Net Income | -70.80M | -124.51M | -63.92M | -52.65M | -62.97M | -53.17M | -18.49M | -21.55M | 6.35M | -13.36M | -11.90M | -24.84M | -8.63M | 8.75M | -2.51M | -75.67M | -103.68M | -20.91M | -11.18M | -2.56M | -1.86M | -2.25M |
| Net Income Ratio | -153.84% | -300.72% | -173.03% | -152.89% | -309.20% | -1,795.71% | -245.19% | -1,330.06% | 23.89% | -384.54% | -555.30% | -704.34% | -173.78% | 37.97% | -20.65% | -2,176.93% | -4,638.70% | -1,427.12% | -1,776.47% | -965.00% | -2,498.46% | -436.07% |
| EPS | -1.82 | -3.34 | -2.22 | -4.10 | -6.04 | -11.50 | -5.23 | -6.81 | 2.16 | -4.87 | -5.16 | -11.95 | -4.43 | 4.76 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -0.84 | -7.32 | -5.48 |
| EPS Diluted | -1.82 | -3.34 | -2.22 | -4.10 | -6.04 | -11.50 | -5.23 | -6.81 | 2.08 | -4.87 | -5.16 | -11.95 | -4.43 | 4.63 | -1.37 | -41.65 | -93.93 | -27.81 | -21.53 | -2.08 | -7.32 | -5.48 |
| Weighted Avg Shares Out | 38.90M | 37.32M | 28.76M | 12.84M | 10.43M | 4.62M | 3.53M | 3.16M | 2.94M | 2.74M | 2.30M | 2.08M | 1.95M | 1.84M | 1.83M | 1.82M | 1.10M | 752.10K | 519.50K | 3.06M | 253.65K | 410.92K |
| Weighted Avg Shares Out (Dil) | 38.90M | 37.32M | 28.76M | 12.84M | 10.43M | 4.62M | 3.53M | 3.16M | 3.06M | 2.74M | 2.30M | 2.08M | 1.95M | 1.89M | 1.83M | 1.82M | 1.10M | 752.10K | 519.50K | 1.23M | 253.65K | 410.92K |
EyePoint Pharmaceuticals: A Puncher's Chance For Long Acting Eye Disease Drug Success
EyePoint is a $200m market cap biotech focused on eye disease. The company's long-acting Durasert technology has been supporting its commercial product, YUTIQ, which earned $28m of revenues in FY22. EyePoint recently announced however that it had sold YUTIQ to...
EyePoint Pharmaceuticals, Inc. (EYPT) Q1 2023 Earnings Call Transcript
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q1 2023 Results Conference Call May 3, 2023 8:30 AM ET Company Participants George Elston - Chief Financial Officer Nancy Lurker - Chief Executive Officer Dr. Jay Duker - President and Chief Operating Officer Scott...
Strength Seen in EyePoint Pharmaceuticals (EYPT): Can Its 9.6% Jump Turn into More Strength?
EyePoint Pharmaceuticals (EYPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at the...
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2022 Financial Results on March 2, 2023
WATERTOWN, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced it will host a conference...
5 Penny Stocks To Buy According To Analysts, Targets Up To 992%
Analysts say these are penny stocks to buy. Do you agree?
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced that EyePoint Pharmaceuticals will present at...
EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2022 Earnings Call Transcript
Start Time: 08:30 January 1, 0000 9:13 AM ET EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT ) Q3 2022 Earnings Conference Call November 02, 2022, 08:30 AM ET Company Participants Nancy Lurker - President and CEO George Elston - CFO Jay Duker -...
EyePoint Pharmaceuticals (EYPT) Reports Q3 Loss, Misses Revenue Estimates
EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of 30% and 0.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
EyePoint Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 2, 2022
WATERTOWN, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced it will host a conference call...
Source: https://incomestatements.info
Category: Stock Reports